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Abstract
Background: Patent ductus arteriosus (PDA) in extremely preterm infants remains a challenging condition with conflicting
treatment strategies. Ibuprofen is currently used to treat PDA with ductal closure failure rate up to 40%. We test the
hypothesis that cytochrome P450 CYP2C8/2C9 polymorphisms may predict ibuprofen response.
Methodology/Principal Findings: We studied extremely preterm neonates with haemodynamically significant PDA and
treated with ibuprofen. One or two variant CYP2C8 and/or 2C9 alleles were found in 17% of the population, most of them
were from Caucasian ethnicity (67–74%). Response to ibuprofen and clinical course of infants carrying variants CYP2C8 and
CYP2C9 were similar. Comparing infants with wild type or variant CYP2C8 and CYP2C9 genotypes, response rate to ibuprofen
was significantly higher in wild type than in mutated carriers in univariate analysis (73% versus 52%, p=0.04). Comparing
responders (ductus closure; n=75) and non-responders (surgical ligation; n=36), the only two factors significantly
associated with the response to ibuprofen using multivariate analysis were higher gestational age and non Caucasian
ethnicity but not CYP2C polymorphism.
Conclusions: CYP2C polymorphism was not associated with PDA response to ibuprofen and this factor appears not
appropriate to optimize the ductal closure rate by modulating ibuprofen dosing strategy. This study points out the role for
ethnicity in the interindividual variability of response to ibuprofen in extremely preterm infants.
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Introduction
Patent ductus arteriosus (PDA) in very preterm infants born
before 28 weeks’gestation remains a challenging condition
regarding the treatment regimens and subsequent clinical
consequences. PDA results in increased pulmonary blood flow
and redistribution of flow to other organs responsible for several
neonatal co-morbidities (ie, brain lesions, chronic lung disease,
necrotizing enterocolitis). The patency of ductus arteriosus is
observed in 55–70% of neonates born before 28 weeks’ gestation,
requiring medical or surgical closure [1]. In France, the
cyclooxygenase inhibitor ibuprofen is currently used to treat
PDA. However, failure of ductal closure is reported in up to 40%
of infants treated with ibuprofen and may be more likely observed
in the very immature neonates, leading to surgical ligation [2–4].
Even if surgery has limited complications, several adverse effects
including pneumothorax, hypotension, intra-operative bleeding,
phrenic nerve palsy, poor neurological outcome and death have
been reported [5,6]. Thus, pharmacologic treatment remains the
first-line treatment [7].
There is still ongoing debate regarding the optimal dosage,
schedule for ibuprofen administration in very preterm infants to
improve ductal closure rate. The possible relationship between
pharmacokinetic parameters and response to ibuprofen has been
extensively investigated with conflicting results [8]. Ibuprofen
serum concentration was found higher in patients with closed
ductus arteriosus compared to patients with PDA after treatment
[8,9]. A higher dose regimen might achieve a greater closure rate;
however, its tolerability and safety should be carefully evaluated as
numerous adverse effects, including impaired renal function have
been observed with ibuprofen treatment in neonates [10].
Another strategy might be to optimize the ductal closure rate by
individualizing therapy regimen according to pharmacogenetic
characteristics. Indeed, ibuprofen is a racemate of R- and S-
enantiomers with 60% of R-ibuprofen being converted into S-
ibuprofen. The racemic mixture undergoes stereoselective cyto-
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lizes S-ibuprofen and CYP2C8 metabolizes R-ibuprofen [11]. Both
metabolic pathways are polymorphic under genetic control with
large inter and intra-ethnic variability [11,12]. Among 34 CYP2C9
alleles, 2 mutated alleles, namely CYP2C9*2 and 2C9*3, were
reported to have a significant impact on the metabolism of many
drugs, including non steroid anti-inflammatory drugs and primarily
ibuprofen and among others, antiepileptic, oral hypoglycaemic, and
anticoagulant drugs. Similarly, among 14 CYP2C8 alleles,
CYP2C8*2 and CYP2C8*3 were associated with reduced enzyme
activity in vitro [13]. In Caucasians, 22% of CYP2C8 genes and 31%
of CYP2C9 genes have mutations with a linkage between the
CYP2C8 and CYP2C9 genetic polymorphisms [14].
Data evaluating the pharmacokinetic consequences and clinical
impact of ibuprofen polymorphic metabolism are available in
adults but data in paediatric patients and primarily in neonates are
lacking [14,15].
Therefore, we tested here if individual CYP2C8/2C9 genotypes
may predict ibuprofen response in extremely preterm infants.
Methods
Patients and ethics
Extremely preterm infants with a gestational age below 28
weeks and admitted in the neonatal intensive care unit (Cre ´teil
Intercommunal Neonatal Intensive Care Unit) between March
2003 and April 2008 were prospectively entered into a
standardized database. Gestational age was based on the date of
the last menstrual period and on ultrasonographic findings during
the first trimester of pregnancy. This study investigated 111
preterm infants with haemodynamically significant PDA (see
below) and treated with ibuprofen, according to ductal response to
treatment. In this monocentric study, all patients were treated and
evaluated similarly along the study period. The study was
approved by the local ethics committee (CCPPRB Henri Mondor),
and written informed consent was obtained from the parents.
Prospective data collection
We created a standard data collection (approved by local ethics
committee) with parental informations, circumstances and route of
the delivery, antenatal treatments (corticosteroid, antibiotics),
neonatal morbidities (neonatal infection, respiratory distress
syndrome, bronchopulmonary dysplasia (defined as oxygen and/
or assisted ventilation requirement at 28 days of life and 36 weeks
of postconceptional age), necrotizing enterocolitis), brain lesions
observed on ultrasound. Standard neonatal cranial ultrasounds
were performed using a 7.5 Mhz transducer (Vivid i ultrasound,
GE Healthcare, Eilat, Israel). They were usually performed using a
standardized scanning procedure, twice within the first week of
life, around 21 days and thereafter at 36 weeks of gestational age.
The main recorded events associated with preterm delivery were
histological chorioamnionitis, premature rupture of amniotic
membranes more than 24 hours before delivery, intrauterine
growth retardation (IUGR, below 10
th percentile according to
Kramer [16]) and preeclampsia. All outcomes, including death,
were recorded until infants were discharged from the hospital.
Criteria for PDA, ibuprofen treatment and evaluation of
treatment response
The medical treatment criteria for patients were evaluated by
colour Doppler ultrasonography using a 10 MHz probe (Vivid i
ultrasound, GE Healthcare, Eilat, Israel). Echocardiographic
criteria for PDA included evidence of left-to-right blood flow
through the open ductus on color Doppler scanning, ductus
diameter $1.4 mm/kg, increased left atrial diameter compared to
aortic root (left-atrium-to-aortic-root ratio $1.4), and left pulmo-
nary artery end diastolic flow velocity .0.2 m/sec as described by
El Hajjar et al [17]. Ibuprofen-trometamol for parenteral use
(PedeaH Orphan Europe laboratory, Paris- La De ´fense, France) was
administrated. Three daily doses of ibuprofen of 10, 5 and 5 mg/kg
were given intravenously over 15 minutes on 3 consecutive days at
24 hours intervals. Ibuprofen administration started between 12
and 72 h of life in most cases (n=100) and was delayed in 11
remaining neonates. Infants with only a partially closed PDA after
the first course of ibuprofen treatment underwent a second course
48 hours after the end of the first course. Responders were defined
as patients without any clinical evidence of PDA and without
luminal flow on Doppler examination 24 hours after the end of
treatment regimen. Non responders underwent surgical ligation.
CYP2C8 and CYP2C9 genotyping procedures
Blood samples were drawn after Institutional Review Board
approval and informed parental consent were obtained. Genomic
deoxyribonucleic acid (DNA) was extracted and kept frozen
at 220uC until analysis.
The main enzymes involved in ibuprofen metabolism are
CYP2C8 and CYP2C9. For CYP2C8, the most common variant
CYP2C8*3 alleles (rs10509681 and rs11572080 were tested but
CYP2C8*2 was not tested. For CYP2C9, CYP2C9*2 (rs1799853)
and CYP2C9*3 (rs1057910) were analyzed. All of the single
nucleotide polymorphisms (SNPs) were detected after real time
polymerase chain reaction (PCR) by the use of 59nuclease allelic
discrimination assays (ABI PRISM 7900HT Sequence detection
system, Applied Biosystems, Foster City, CA). They were analyzed
by commercial assays (TaqMan DME assays, Applied Biosystems)
and the PCR conditions were identical to those of the
manufacturer’s instructions.
Statistical methods
Results are expressed as median (range) for quantitative
variables and absolute numbers (percentages) for qualitative
variables. Comparisons between CYP genotype and between
responses to treatment were performed with non parametric tests:
Chi-2 or Fischer exact test as appropriate for qualitative variables,
Wilcoxon test for quantitative variables. Patients were divided into
two groups according to CYP2C8 and 2C9 genotypes: patients
homozygous wild type for both genes (wild type patients) and
patients homozygous or heterozygous mutated for one or both
genes (mutated patients).
Logistic regression model was used to assess the relationship
between response to treatment and wild type, neonate sex,
postmenstrual age, ethnicity and multiple pregnancies. Model
selection used a stepwise backward-forward procedure. Results
were expressed in bivariate analyses and at the last step of the
stepwise procedure as odds ratios (OR) and 95% confidence
interval (95% CI). Goodness-of-fit for the logistic regression model
was tested using the Hosmer-Lemeshow chi-square test and
discrimination by the c-statistic.
All tests were bilateral and level of statistical significance was set
at 0.05. Statistical analyses were carried out using SAS 9.1 (SAS
Inc, Cary, NC).
Results
Genotyping of neonates with PDA for CYP2C8 and
CYP2C9 polymorphisms
Genotype frequencies for CYP2C8 and CYP2C9 (n=111) are
presented table 1. The frequencies of CYP2C8*1/*1, *1/*3 and
PDA and Cytochrome P450
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frequencies of alleles CYP2C9*1/*1(77%), *1/*2(15%); *1/
*3(5%), *2/*2(1%), *2/*3(1%) and *3/*3(1%) did not differ
significantly from those observed in previous reports [14,18]. Most
infants carrying the CYP2C8*3 allele were also carriers of
CYP2C9*2. The number of patients carrying various combinations
of both alleles (17/27) is higher than expected from the allele’s
frequencies suggested that there is a linkage between CYP2C8 and
CYP2C9 variant alleles. No association between CYP2C8*3 and the
other CYP2C9 alleles was observed. Because different polymor-
phisms could induce different changes in ibuprofen pharmacoki-
netics and/or pharmacodynamics, we first analyzed clinical
characteristics of CYP2C8*3 carriers compared with CYP2C9*3
carriers. No difference between these two groups was observed in
both perinatal characteristics and ibuprofen response. Therefore,
all mutated subjects were analyzed in the same group.
Perinatal characteristics of neonates according to
CYP2C8 and CYP2C9 genotyping
Tables 2 and 3 show the perinatal characteristics of neonates
with PDA according to individual CYP2C8 and CYP2C9
genotypes (wild type n=84 or mutated n=27). Among our
patients, statistically significant associations were observed
between variant alleles for CYP2C8 and CYP2C9 and Caucasian
ethnicity of both parents. In contrast, gestational age, birth
weight, circumstances of preterm delivery and IUGR were not
found associated with CYP genotypes. In postnatal period, we
found a significant association between variant alleles carriers and
a longer total ventilation duration (p=0.01). However, there was
no difference in chronic lung disease incidence or postnatal
steroids use in this variant subpopulation. Severe brain lesions
(high grades intraventricular haemorrhage and cystic periven-
tricular leukomalacia) and neonatal mortality were not found
different between the two groups.
Surprisingly, response rate to ibuprofen treatment was found
significantly higher in wild type carriers that in mutated carriers of
CYP2C8 and CYP2C9 (73% vs 52%, p=0.04). This result was
unexpected with regard to the potential pharmacokinetics
consequences of CYP2C8 and CYP2C9 variant alleles on the
clearance of ibuprofen. Therefore, subsequent analysis of the
cohort compared responders to non responders’ neonates to
ibuprofen treatment to investigate potential confounding variables
mitigating any effect of CYP2C8 and CYP2C9 variants.
Perinatal characteristics of neonates according to the
response to ibuprofen treatment
Tables 4 and 5 describe the perinatal characteristics of neonates
with PDA according the response to ibuprofen treatment. Among
the cohort of patients, statistically significant associations were
observed between non responders and Caucasian ethnicity of the
mother (p=0.01), multiple pregnancies (p=0.03), birth weight
(p=0.009) and a lower gestational age (p,0.0001). In contrast,
circumstances of preterm delivery and IUGR were not found
associated with clinical response to ibuprofen. As expected in
postnatal period,non responders required mechanical ventilation 3-
fold longer than responders and chronic lung disease incidence and
postnatal steroids use were higher in non responders patients
(p=0.02 and p=0.001, respectively). Severe brain lesions (high
grades IVH and cystic periventric‘ular leukomalacia) and neonatal
mortality were found not different between the two groups. In
bivariate analyses, responders patients were found more likely to
carry wild typegenotype for CYP2C8 and CYP2C9compared to non
responders (81% vs 64%, p=0.05). Using multivariable analysis,
higher gestational age at birth (OR 2.6 95%CI 1.6–4.1) and non
Caucasian ethnicity (OR 3.9 95%IC 1.5–10.1) (but not CYP
genotype) were found to be statistically associated with the response
to ibuprofen in extremely preterm neonates with PDA (Table 6).
Discussion
We have hypothesized that, in addition to prematurity and envi-
ronmental factors, efficacy of ibuprofen to treat PDA was related to
pharmacogenetics factors affecting ibuprofen metabolism and phar-
macokinetics. The goal of this study was to determine the contri-
bution of these pharmacogenetic factors to ibuprofen response and
thepotentialrelevance ofgenotype-based dosing of ibuprofen likelyto
increase PDA closure rate and subsequent neonatal morbidity.
Relationship between area under the curve and ibuprofen
efficacy for PDA closure was reported in several studies [10,18].
Therefore, it might be expected that genetic polymorphisms
reducing ibuprofen metabolism would increase drug effectiveness.
Interindividual variability in drug metabolism may account for
clinical differences in therapeutic efficacy or adverse effects
associated to ibuprofen treatment.
The CYP2C9 enzyme plays a key role in the formation of
oxidative metabolites of both R-(inactive 2) and S-(active +)
ibuprofen [11,19]. In vitro studies indicate that stereoselectivity of
ibuprofen hydroxylation by human CYPs exists, CYP2C8 being the
main enzyme involved in the hydroxylation of R-(2)-ibuprofen and
CYP2C9 being the main enzyme involved in the hydroxylation of
S-(+)-ibuprofen [19]. In adults, low ibuprofen clearance occurring is
strongly linked to CYP2C8 and CYP2C9 polymorphism [14,20].
We tested the major CYP2C8 and CYP2C9 allelic variants
known to reduce ibuprofen clearance in healthy adults [2,14] but
our findings do not support the hypothesis that clinical response to
ibuprofen could be related to CYP2C8 and 2C9 genotypes in
extremely preterm infants.
Variant alleles frequencies observed in the present study were
consistent with published data. CYP variants were described more
frequently in Caucasian than in non Caucasian populations [21].
In Caucasians, reported CYP2C allele frequencies were 9.5 to
17% for CYP2C8*3 and 16 to 21% for CYP2C9*2 [18] as
compared to 17% for both of these alleles in our study. In
agreement with previous findings, a gene linkage between
CYP2C8*3 and CYP2C9*2 alleles was observed.
The absence of association between CYP2C polymorphisms
and response to ibuprofen in extremely preterm infants might be
related to other several factors:
Table 1. Polymorphisms frequencies (N, (%)) of CYP2C8 and
CYP2C9 in population (n=111).
CYP2C8
*1/*1 *1/*3 *3/*3 All
CYP2C9 *1/*1 84 (76%) 2 (2%) 86 (77%)
*1/*2 2 (2%) 15 (14%) 17 (15%)
*1/*3 5 (5%) 5 (5%)
*2/*2 1 (1%) 1 (1%)
*2/*3 1 (1%) 1 (1%)
*3/*3 1 (1%) 1 (1%)
All 92 (83%) 18 (16%) 1 (1%)
doi:10.1371/journal.pone.0012329.t001
PDA and Cytochrome P450
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Wild Type
n=84
Mutated
n=27 P
Male 44 (52%) 16 (59%) 0.53
Mother ethnicity 0.006
Caucasian 31 (37%) 18 (67%)
Other 53 (63%) 9 (33%)
Father ethnicity 0.001
Caucasian 32 (39%) 20 (74%)
Other 51 (61%) 7 (26%)
Caesarian section 40 (48%) 10 (37%) 0.33
Multiple pregnancies 23 (27%) 8 (30%) 0.82
Median birth weight (g), (range) 817 800 0.39
(490–1290) (530–1410)
Median gestational age (weeks), (range) 26.3 26.0 0.07
(24.3–27.9) (24.1–27.7)
Vascular placental disease 20 (24%) 4 (15%) 0.32
Preterm labour 65 (77%) 24 (89%) 0.19
Histological chorioamnionitis 41/80 (51%) 13/26 (50%) 0.91
Rupture of membranes .12 h 15 (18%) 5 (19%) 1.00
Antenatal betamethasone 79 (94%) 25 (93%) 0.68
IUGR,10 perc. 19 (23%) 5 (19%) 0.65
IUGR: intra uterine growth retardation.
doi:10.1371/journal.pone.0012329.t002
Table 3. Clinical characteristics of the population according to CYP genotype.
Wild type
n=84
Mutated
n=27 P
Additional surfactant 23 (27%) 13 (48%) 0.04
Haemodynamic support 13 (15%) 1 (4%) 0.18
Neonatal sepsis 9 (11%) 0 (0%) 0.11
Nosocomial sepsis 20 (24%) 3 (11%) 0.16
Median duration of total Ventilation 33.5 41.5 0.01
(days) (range) (1.4–71.0) (21.1–73.0)
Median duration of mechanical ventilation
(days) (range)
12.1
(0.2–52.2)
18.9
(0.6–73.0)
0.04
Median duration of non invasive ventilation
(days) (range)
20.5
0.2–42.8
23.8
0–35.3
0.06
Chronic lung disease at 36 weeks 12 (15%) 4 (15%) 1.00
Postnatal systemic steroids 45 (56%) 17 (63%) 0.50
Inhaled steroids 50 (62%) 19 (70%) 0.42
Necrotizing enterocolitis 2 (2%) 2 (7%) 0.26
IVH all grades 20 (24%) 5 (19%) 0.57
IVH grades III-IV 3 (3%) 2 (7%) NC
Cystic periventricular leucomalacia 1 (1%) 0 NC
Death before discharge 3 (4%) 0 (0%) NC
Response to ibuprofen 61 (73%) 14 (52%) 0.04
IVH: intraventricular haemorrhage.
doi:10.1371/journal.pone.0012329.t003
PDA and Cytochrome P450
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remains heterogeneous in terms of preterm birth circum-
stances and severity of respiratory disease, two factors
involved in the severity and clinical consequences of PDA.
Moreover, the sample size of the studied population remains
quite low.
Table 4. Perinatal characteristics of the population according to the response to Iboprofen.
Responders
n=75
Non responders
n=36 P
Male 44 (59%) 16 (44%) 0.16
Mother ethnicity 0.01
Caucasian 27 (36%) 22 (61%)
Other 48 (64%) 14 (39%)
Father ethnicity 0.07
Caucasian 31 (41%) 21 (60%)
Other 44 (59%) 14 (40%)
Caesarian section 35 (47%) 15 (42%) 0.62
Multiple pregnancies 16 (21%) 15 (42%) 0.03
Median birth weight (g) 880 768 0.01
(range) (490–1410) (490–1170)
Median postmenstrual age, weeks 26.6 25.6 ,0.0001
(range) (24.4–27.9) (24.1–27.9)
Vascular placental disease 19 (25%) 5 (14%) 0.17
Preterm labour 57 (76%) 32 (89%) 0.11
Histological chorioamnionitis 34/70(49%) 20/36(56%) 0.50
Rupture of membranes .12 h 16 (21%) 4 (11%) 0.19
Antenatal betamethasone 69 (92%) 35 (97%) 0.42
IUGR,10 perc. 17 (23%) 7 (19%) 0.70
doi:10.1371/journal.pone.0012329.t004
Table 5. Clinical characteristics of the population according to the response to Ibuprofen.
Responders
n=75
Non responders
n=36 P
Additional Surfactant 20 (27%) 16 (44%) 0.06
Haemodynamic support 11 (15%) 3 (8%) 0.54
Neonatal sepsis 5 (7%) 4 (11%) 0.47
Nosocomial sepsis 14 (19%) 9 (25%) 0.44
Median duration of total ventilation (days) (range) 28.6
(1.4–62.9)
46.3
(10.4–73.0)
,0.0001
Median duration of mechanical ventilation (days) (range) 6.9
(0.2–35.5)
22.2
(3.4–73.0)
,0.0001
Median duration of non invasive ventilation (days) (range) 20.6
(0.2–41.7)
23.2
(0–42.8)
0.16
Chronic lung disease at 36 weeks 7 (9%) 9 (26%) 0.02
Postnatal systemic steroids ,36weeks 36 (49%) 26 (76%) 0.007
Inhaled steroids 44 (59%) 25 (74%) 0.16
Necrotizing enterocolitis 0 (0%) 4 (11%) 0.01
IVH all grades 16 (21%) 9 (25%) 0.67
IVH grade III-IV 2 (2%) 3 (8%) NC
Cystic periventricular leucomalacia 1 (1%) 0 (0%) NC
Death before discharge 1 (1%) 2 (6%) 0.24
Wild Type CYP2C8 and 2C9 61 (81%) 23 (64%) 0.04
doi:10.1371/journal.pone.0012329.t005
PDA and Cytochrome P450
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may be developmentally influenced [22]. CYP2C protein
expression and/or catalytic activity are most probably very
low during the immediate postnatal period in very low birth
weight infants. Indeed, CYP2C9-specific content and catalytic
activity were consistent with expression at 1 to 2% of mature
values during the first trimester of pregnancy, with progressive
increase during the second and third trimesters to reach
approximately 30% of mature values [23]. However, Koukour-
itaki et al. and others demonstrated that CYP2C maturation
depends only on postnatal age and 51% of newborns exhibiting
values close to mature levels suggesting that the most immature
neonates could express a substantial amount of CYP [24].
N CYP 2C8/9 has been identified as an endothelium-derived
hyperpolarizing factor (EDHF) synthase who is a physiologi-
cally relevant generator of reactive oxygen species (ROS) in
vascular endothelial cells and modulates both vascular tone
and homeostasis [25]. A decreased expression of CYP2C could
reduce ROS accumulation and subsequent PDA closure [26].
N Some other ibuprofen metabolites may influence the clinical
response of this drug deserving further testing through
metabolomics studies [27].
N Finally, CYP2C8 was found involved in the metabolism of
arachidonic acid to biologically active epoxyeicosetrenoic acids
(EETs) in the kidney. Indeed, CYP2C8*3 variant was associated
with a reduced turnover of arachidonic acid to11,12-EET and
14,15-EET [13]. These epoxides have significant physiologic
role in water reabsorption and Na+ transport, inflammation,
and vascular smooth muscle tone [28–30] all factors likely to
modulate vascular tone and to alter ductus closure.
In addition to CYP2C polymorphism, other genetic factors and
ethnicity could also mitigate the impact of CYP2C genotype on
response to ibuprofen. In addition to gestational age, ethnicity was
strongly associated with the response to ibuprofen and PDA closure
in the present study. The awareness of ethnic/racial disparities in
neonatal care of preterm infants has been growing because of
considerable data gathered from recent clinical and experimental
studies. For example, it is clear that there is a 2- to 3-fold racial
difference in preeclampsia associated dysfunctional vasodilatation
[31]. Similarly, common genetic variants in genes encoding pro- or
anti-inflammatory cytokines may influence the risk for spontaneous
preterm birth. It has been shown that genetic factors may also
influence the susceptibility to white matter damage and subsequent
cerebral palsy in very preterm infants [32–35]. In rodents, strains
disparities have been reported to account for differences in brain
vulnerability to neonatal hypoxic-ischemic insult [36]. Recently, two
reportssupportthatpretermPDAishighlyfamilialwithcontribution
ofboth geneticand environmental factors [37,38]. Moreover,ductus
remodeling, likely genetically determined, was recognized as one of
the most important factors for PDA closure [39].
Ethnic disparities in neonatal and post-neonatal mortality,
documented in the United States, is related to many factors both
genetic and epigenetic, including health care disparities, differences
in risk factors and causes of neonatal mortality, differences in drug
efficacy [40]. African Americans experience a lower risk of neonatal
mortality in preterm and low birth weight infants compared to white
or hispanic ethnic groups [41]. In contrast, after surfactant therapy
for RDS became generally available, neonatal mortality improved
morefor white than for black infants with verylow birth weight [42].
AfricanAmericaninfantshavebeenshowntohavealowerincidence
of RDS than whites after controlling for birth and gestational age
[43,44]. This observation is consistent with the present study
showing a significantly higher incidence of additional surfactant
requirement in CYP2C variant infants who were tightly associated
with Caucasian ethnicity. These differences have been attributed to
more rapid lung maturation and consequently earlier production of
pulmonary surfactant in African American foetuses compared with
white foetuses [45–47]. Altogether, these data support that, in
addition to environmental or sociodemographic factors, genetically-
determined ethnic differences account for disparities in respiratory
illness and response to treatment in VLBW neonates. Our study
suggests that similar conclusions could be made for PDA closure and
response to ibuprofen but unrelated to CYP2C genotype.
In conclusion, CYP2C8 and 2C9 polymorphisms did not appear
to be involved in PDA response to ibuprofen and cannot be used
to optimize the ductal closure rate by modulating ibuprofen dosing
strategy. In contrast, this study points out the role for ethnicity in
the interindividual variability of response to ibuprofen and
subsequent PDA closure in preterm infants. Interethnic differences
in the neonatal PDA clinical course should be further explored and
correlated to ibuprofen pharmacokinetics.
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doi:10.1371/journal.pone.0012329.t006
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